• KCSA Strategic Communications has signed an agreement to provide investor relations services to Mindset Pharma (MSET)
  • KCSA is a fully integrated communications consultancy firm that will provide strategic support for Mindset’s research of next-generation psychedelic compounds
  • Mindset Pharma is a drug discovery and development company focused on creating psychedelic medicines
  • Mindset Pharma Inc. (MSET) is up 1.85 per cent and is currently trading at $0.55 per share

KCSA Strategic Communications has signed an agreement to provide investor relations services to Mindset Pharma (MSET).

The agreement, effective May 15, has an initial term of six months.

KCSA is a fully integrated communications consultancy with a creative and strategic approach to public relations, investor relations and social media.

Mindset Pharma is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

KCSA will provide strategic support for this research by reaching out to potential investors and marketing the compound.

Jeffrey Goldberger, managing partner and principal of KCSA Strategic Communications commented,

“KCSA is excited to partner with the management team of Mindset to help increase investor awareness of this very exciting CNS-focused drug development company.”

Jeffrey added,

“As a firm dedicated to supporting the medical psychedelics industry, KCSA is well versed in the sector and is confident the underlying science of psychedelic compounds holds great promise in treating a variety of psychiatric disorders.”

The agreement may be terminated with 90 days’ written notice by either party following the conclusion of the initial six-month term.

Mindset Pharma is a drug discovery and development company focused on creating psychedelic medicines to treat neurological and psychiatric disorders.

Mindset Pharma Inc. (MSET) is up 1.85 per cent and is trading at $0.55 per share as of 3:59 pm ET. 

More From The Market Online

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.